REFERENCES
- Marangos PJ, Schmechel D, Zis AP, Goodwin FK. The existence and neurobiological significance of neuronal and glial forms of the glycolytic enzyme enolase. Biol Psychiatr 1979; 14: 563–79.
- Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F. Increased serum creatine kinase BB and neuron-specific enolase following head injury indicates brain damage. Acta Neurochir (Wien) 1992; 115: 106 — 11.
- Hardemark H-G, Ericsson N, Kotwica Z, et al. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg 1989; 71: 727 — 31.
- Dauberschmidt R, Marangos PJ, Zinmeyer J, Bender V, Klages G, Gross J. Severe head trauma and the changes of concentration of neuron-specific enolase in plasma and in cerebrospinal fluid. Clin Chim Acta 1983; 131: 165 — 70.
- Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neuro-surg 1996; 10: 471 —6.
- Mokuno K, Kiyosawa K, Sugimura K, et al. Prog-nostic value of cerebrospinal fluid neuron-specific enolase and 5-100b protein in Guillain-Barre syndrome. Acta Neurol Scand 1994; 89: 27— 30.
- Mokuno K, Kato K, Kawai K, Matsuoka Y, Yanagi T, Sobue I. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neu-rol Sci 1983; 60: 443 — 51.
- DeGiorgio CM, Correale JD, Gott PS, et al. Serum neuron — specific enolase in human status epilepticus. Neurology 1995; 45: 1134–7.
- Jimi T, Wakayama Y, Shibuya S, et al. High levels of nervous system — specific proteins in cerebro-spinal fluid in patients with early stage Creutzfeldt — Jacob disease. Clin Chim Acta 1992; 211: 37–46.
- Sulkava R, Viinikka L, Erkinjuntti T, Roine R. Cerebrospinal fluid neuron-specific enolase is decreased in multi-infarct dementia, but unchanged in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 549 — 51.
- van de Pol M, Twijnstra A, ten Velde GP, Menheere PP. Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma. J Neurooncol 1994; 19: 149 — 54.
- Beelen NA, Twijnstra A, van dePol M, Menheere PP. Neuron-specific enolase in cerebrospinal fluid of patients with metastatic and non-metastatic neu-rological disease. Eur J Cancer 1993; 29A: 193 — 5.
- Persson L, Hardemark HG, Gustafsson J, et al. S-100 protein and neuron-specific enolase in cere-brospinal fluid and serum: markers of cell damage in human central nervous tissue. Stroke 1987; 18: 911— 18.
- Paus E, Nustad K. Immunoradiometric assay for ay and yy — enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetiz-able polymer particles. Clin Chem 1989; 35: 2034 — 8.
- Prolifigeng NSE IRMA. Instructions for use. Sangtec Medical AB, Bromma, Sweden, June 1996
- van Engelen BGM, Lamers KJB, Gabreels FJM, Wevers RA, van Geel WJA, Borm GF. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cere-brospinal fluid. Clin Chem 1992; 38: 813— 16.
- Lamers KJB, van Engelen BGM, Gabreels FJM, Hommes OR, Borm GF, Wevers RA. Cerebro-spinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995; 92: 247 — 51.
- Royds JA, Timberly WR, Taylor CB. Levels of enolase and other enzymes in the cerebrospinal fluid as indices of pathological change. J Neurol Neurosurg Psychiatry 1981; 44: 1129 — 35.
- Henriksson L, Voigt K. Age-dependent difference of distribution and clearance patterns in normal RIHSA cisternograms. Neuroradiology 1976; 12: 103–7.
- Loefberg H, Grubb AO, Sveger T, Olsson JE. The cerebrospinal fluid and plasma concentrations of gamma-trace beta2 microglobulin at various ages and in neurological disorders. J Neurol 1980; 223: 159— 70.